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Abstract
Background: The dietary methylamines choline, carnitine, and phosphatidylcholine are used by the gut microbiota
to produce a range of metabolites, including trimethylamine (TMA). However, little is known about the use of
trimethylamine N-oxide (TMAO) by this consortium of microbes.
Results: A feeding study using deuterated TMAO in C57BL6/J mice demonstrated microbial conversion of TMAO to
TMA, with uptake of TMA into the bloodstream and its conversion to TMAO. Microbial activity necessary to convert
TMAO to TMA was suppressed in antibiotic-treated mice, with deuterated TMAO being taken up directly into the
bloodstream. In batch-culture fermentation systems inoculated with human faeces, growth of Enterobacteriaceae
was stimulated in the presence of TMAO. Human-derived faecal and caecal bacteria (n = 66 isolates) were screened
on solid and liquid media for their ability to use TMAO, with metabolites in spent media analysed by 1H-NMR. As
with the in vitro fermentation experiments, TMAO stimulated the growth of Enterobacteriaceae; these bacteria produced
most TMA from TMAO. Caecal/small intestinal isolates of Escherichia coli produced more TMA from TMAO than their
faecal counterparts. Lactic acid bacteria produced increased amounts of lactate when grown in the presence of TMAO
but did not produce large amounts of TMA. Clostridia (sensu stricto), bifidobacteria, and coriobacteria were significantly
correlated with TMA production in the mixed fermentation system but did not produce notable quantities of TMA from
TMAO in pure culture.
Conclusions: Reduction of TMAO by the gut microbiota (predominantly Enterobacteriaceae) to TMA followed by host
uptake of TMA into the bloodstream from the intestine and its conversion back to TMAO by host hepatic enzymes is an
example of metabolic retroconversion. TMAO influences microbial metabolism depending on isolation source and taxon
of gut bacterium. Correlation of metabolomic and abundance data from mixed microbiota fermentation systems did not
give a true picture of which members of the gut microbiota were responsible for converting TMAO to TMA; only
by supplementing the study with pure culture work and additional metabolomics was it possible to increase our
understanding of TMAO bioconversions by the human gut microbiota.
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Background
Dietary methylamines such as choline, trimethylamine
N-oxide (TMAO), phosphatidylcholine (PC), and carni-
tine are present in a number of foodstuffs, including
meat, fish, nuts, and eggs. It has long been known that
gut bacteria are able to use choline in a fermentation-
like process, with trimethylamine (TMA), ethanol,
acetate, and ATP among the known main end products
[1–3]. TMA can be used by members of the order
Methanomassiliicoccales (Archaea) present in the hu-
man gut to produce methane [4], or taken up by the
host. Microbially produced TMA derived from PC is
absorbed in the small intestine [5]. TMA diffuses into
the bloodstream from the intestine via the hepatic vein
to hepatocytes, where it is converted to trimethylamine
N-oxide (TMAO) by hepatic flavin-containing mono-
oxygenases (FMOs) [6]. The bulk of TMAO, and lesser
amounts of TMA, derived from dietary methylamines
can be detected in urine within 6 h of ingestion, and
both compounds are excreted in urine but not faeces [7,
8]. TMAO can also be detected in human skeletal
muscle within 6 h of an oral dose of TMAO [8].
TMAO present in urine and plasma is considered a bio-
marker for non-alcoholic fatty liver disease (NAFLD), in-
sulin resistance, and cardiovascular disease (CVD) [9–12].
Feeding TMAO to high-fat-fed C57BL/6 mice exacerbates
impaired glucose tolerance, though the effect on the gut
microbiota is unknown [13]. Low plasma PC and high
urinary methylamines (including TMAO) were observed
in insulin-resistant mice on a high-fat diet, leading to the
suggestion microbial methylamine metabolism directly
influences choline bioavailability; however, the microbiota
of the mice was not studied nor was labelled choline used
to determine the metabolic fate of TMA/TMAO [9].
Choline bioavailability is thought to contribute to hepatic
steatosis in patients [11]. Spencer et al. [11] manipulated
dietary choline levels in 15 females for 2 weeks and moni-
tored changes in the faecal microbiota during the inter-
vention. They found the level of choline supplementation
affected Gammaproteobacteria (inhibited by high levels of
dietary choline, negatively correlated with changes in liver
fat/spleen fat ratios) and Erysipelotrichi (positively corre-
lated with changes in liver fat/spleen fat ratios), suggesting
baseline levels of these taxa may predict the susceptibility
of an individual to liver disease. However, the study was
under-powered and requires replication with a much
larger cohort to fully examine the link between choline
bioavailability and liver disease. High levels of circulating
TMAO are associated with CVD [12], potentially via a
platelet-mediated mechanism [14]. Circulating TMAO
has been suggested to play a role in protection from
hyperammonemia in mice, acting as an osmoprotectant,
and from glutamate neurotoxicity in mice and primary
cultures of neurons [15, 16]. Recently, chronic exposure to
TMAO was shown to attenuate diet-associated impaired
glucose tolerance in mice and reduce endoplasmic
reticulum stress and adipogenesis in adipocytes [10]. The
relevance of these findings to human health remains to be
determined. There is a basal level of TMA and TMAO
detected in human urine even in the absence of dietary
supplementation [17], suggesting the use of (microbial
and/or host) cell-derived choline or PC in the intestinal
tract by the gut microbiota.
While it is well established that choline [2, 11, 18], PC
[2, 12], and carnitine [19–22] are used by the human
and rodent gut microbiotas to produce TMA, little is
known about the reduction of TMAO (predominantly
from fish) to TMA (or other compounds) by members
of these consortia. TMAO is found at concentrations of
20–120 mg per 100 g fish fillet [23]. Ingestion of fish by
humans leads to increased urinary excretion of dimethy-
lamine (DMA) and TMA, from 5.6 to 24.1 and from 0.2
to 1.6 μmol/24 h/kg of body weight, respectively [24].
Individuals with trimethylaminuria (fish odour syn-
drome), in which TMA is not detoxified to TMAO by
hepatic FMOs, have been shown to reduce 40–60% of
an oral dose of TMAO to TMA [25]. It was suggested
the gut microbiota was responsible for reducing TMAO
in these individuals, and in those individuals without
trimethylaminuria, the TMA was re-oxidized in the liver
before being excreted in the urine. The process was
termed “metabolic retroversion” “(i.e. a cycle of reductive
followed by oxidative reactions to regenerate TMAO)”
[25]. The reduction of TMAO to TMA is most com-
monly associated with the gut microbiota of marine fish,
with the TMA generated by these bacteria contributing
to the characteristic odour of rotting fish [26]. Members
of the class Gammaproteobacteria, which includes a
number of food spoilage organisms, are known to reduce
TMAO to TMA quantitatively and are unable to reduce
TMA further [26, 27]. The conversion of TMAO to
TMA by bacteria represents a unique form of anaerobic
respiration, in which TMAO reductase acts as a terminal
electron acceptor (from NADH or formate) for respira-
tory electron flow [27].
Mining of metagenomic data (torA) suggests Proteo-
bacteria (particularly Escherichia and Klebsiella spp.) are
likely to contribute greatest to the production of TMA
from TMAO in the human gut via the TMAO reductase
pathway, with Actinobacteria (Eggerthellaceae) becoming
more important under stress [28]. Other microbial genes
are associated with production of TMA from choline
(cutC), glycine-betaine (grdH), L-carnitine (cntA), and
γ-butyrobetaine (cntA) [4]. A search of the NCBI nu-
cleotide database with the phrase “TMAO reductase”
also suggests many other bacteria of human intestinal
origin (namely, Salmonella, Helicobacter, Prevotella,
Bacillus, and Bacteroides spp.) should be able to reduce
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TMAO to TMA. However, this trait has not been exam-
ined in vitro for isolates of intestinal origin.
Consequently, we carried out an in vivo study in mice
to confirm the use of TMAO by the mouse gut micro-
biota and to allow us to examine metabolic retroconver-
sion of TMAO in a murine model. We then used an in
vitro fermentation system to highlight the effect of
TMAO on the human faecal microbiota. Finally, we
screened a panel of human faecal and caecal/small intes-
tinal isolates to determine which members of the human
gut microbiota were able to reduce TMAO to TMA and
whether their metabolism was affected by being grown
in the presence of TMAO.
Methods
Animal work
Groups of 6-week-old C57BL6/J mice (Janvier Labs,
Courtaboeuf, France) were received and acclimated in
specific pathogen-free (SPF) maintenance conditions.
They were fed with a standard chow diet (R04-40, Safe,
Augy, France) and were either given free access to tap water
or tap water containing the antibiotic cocktail (0.5 g/L
vancomycin hydrochloride, 1 g/L neomycin trisulfate, 1 g/L
metronidazole, 1 g/L ampicillin sodium; all antibiotics were
purchased from Sigma-Aldrich) for 14 days. Mice were
given in the morning by gavage either a solution of
d9-TMAO at 1 × 10
−4 M (Cambridge Isotope Laboratories
Inc., DLM-4779-0, UK) or saline and euthanized 6 h later
by cervical dislocation. Blood samples were collected by tail
tipping every 2 h in Microvette® CB 300 Lithium Heparin
(Sarstedt, Marnay, France). Plasma was separated by centri-
fugation (10 min, 5000g, 4 °C) and stored at − 80 °C until
analysed by ultra-performance liquid chromatography–tan-
dem mass spectrometry (UPLC–MS/MS).
UPLC–MS/MS determination of plasma TMA, d9-TMA,
TMAO, and d9-TMAO
UPLC–MS/MS was employed for the determination of
TMA, d9-TMA, TMAO, and d9-TMAO. Samples (10 μL)
were spiked with 10 μL internal standard solution (d9-cho-
line and 13C3/
15N-TMA in water; 1 mg/L, Sigma-Aldrich).
Ethyl 2-bromoacetate solution (45 μL) (15 g/L ethyl 2-bro-
moacetate, 1% NH4OH in acetonitrile; ChromaSolv grade,
Sigma-Aldrich) was added and derivatization of TMAs
(TMA, d9-TMA, and
13C3/
15N-TMA) to their ethoxy
analogues was completed after 30 min at room
temperature. Protein/lipid precipitation solution (935 μL)
(94% acetonitrile/5% water/1% formic acid; ChromaSolv
grade, Sigma-Aldrich) was added; samples were centri-
fuged (20 min, 20,000g, 4 °C) and were transferred to
UPLC autosampler vials. Sample injections (5 μL loop)
were performed with a Waters Acquity UPLC-Xevo TQ-S
UPLC–MS/MS system equipped with an Acquity BEH
HILIC (2.1 × 100 mm, 1.7 μm) chromatographic column.
An isocratic elution was applied with 10 mM ammonium
formate (Sigma-Aldrich) in 95:5 (v/v) acetronitrile/water for
7 min at 750 μL/min and 50 °C. Positive electrospray (ESI+)
was used as ionization source, and mass spectrometer
parameters were set as follows: capillary, cone, and sources
voltages at − 700, − 18, and 50 V, respectively, and
desolvation temperature at 600 °C; desolvation/cone/
nebulizer gases were high-purity nitrogen (BOC) at 1000 L/
h, 150 L/h, and 7 bar, respectively. Collision gas was high-
purity argon (BOC). Mass spectrometer was operated in
multiple reaction monitoring mode. The monitored transi-
tions were the following: for TMA, + 146 → + 118/59 m/z
(23/27 V); for d9-TMA, + 155 → + 127/68 m/z (21/23 V);
for 13C3/
15N-TMA, + 150 → + 63/122 m/z (27/22 V); for
TMAO, + 76 → + 59/58 m/z (12/13 V); for d9-TMAO, +
85 → + 68/66 m/z (18/20 V); and for d9-choline, + 108 →
+ 60/45 m/z (20/22 V). The system was controlled by
MassLynx software, also used for data acquisition
and analysis.
1H-NMR spectroscopy and data analysis
Medium samples were randomized and centrifuged
(5 min, 16,000g). Aliquots (50 μL) of the supernatants were
diluted in 550 μL D2O containing 1 mM trimethylsilyl-
(2,2,3,3-2H4)-1-propionate. Samples were transferred to
5 mm NMR tubes and measured on a NMR spectrometer
(Bruker) operating at 600.22 MHz 1H frequency as
described [29]. 1H-NMR spectra were pre-processed and
analysed as described [9] using the Statistical Recoupling of
Variables algorithm [30]. Structural assignment was per-
formed as described [31], using in-house and publicly avail-
able databases.
In vitro fermentation systems
Freshly voided faecal samples were obtained from three
healthy human volunteers (one male and two females;
age range 29–31 years), none of whom had been pre-
scribed antibiotics 6 months prior to the study, eaten
fish 3 days prior to sample collection, or had any history
of gastrointestinal disease. The University of Reading’s
Research Ethics Committee (UREC) does not require
that specific ethical review and approval be given by
UREC for the collection of faecal samples from healthy
human volunteers to inoculate in vitro fermentation
systems. Samples were processed immediately by dilut-
ing them 1 in 10 (w/w) in pre-reduced minimal broth
and homogenizing them in a filter bag in a stomacher
(Stomacher 400 Lab System; Seward) for 2 min at “high”
speed. For each donor, a batch culture vessel containing
175 mL of pre-reduced minimal broth was inoculated
with 20 mL of the faecal homogenate and 5 mL of sterile
H2O containing 2 g TMAO dihydrate (Sigma-Aldrich).
Control vessels were inoculated with 20 mL of the faecal
homogenate and 5 mL of sterile H2O. The final working
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volume of each batch culture vessel was 200 mL. The
pH of each vessel (pH 6.5) was controlled automatically
by the addition of 2 M HCl or 2 M NaOH. pH control-
lers were supplied by Electrolab. The contents of each
vessel were stirred constantly. An anaerobic environ-
ment was maintained by constantly sparging the vessels
with O2-free N2. The temperature of each vessel was
maintained at 37 °C by the use of a circulating waterbath
connected to each fermentation vessel. The experiment
was run for 9 h, with samples taken at 0, 1, 2, 3, 4, 5, 6,
and 9 h.
Fluorescence in situ hybridization (FISH) analysis
Aliquots (2 × 375 μL) of sample were fixed in ice-cold
4% paraformaldehyde for 4 h, washed in sterile
phosphate-buffered saline, and stored for FISH analysis
as described [32]. Additional file 1: Table S1 gives details
for probes used in this study. Probes were synthesized
commercially (MWG-Biotech) and labelled with the
fluorescent dye cyanine 3 (Cy3; excitation λ, 514 nm;
emission λ, 566 nm; fluorescence colour, orange–red).
FISH was done as described [32].
Slides were viewed under a Nikon E400 Eclipse
microscope. DAPI slides were visualized with the aid of
a DM400 filter; probe slides were visualized with the
aid of a DM575 filter. Cells (between 15 and 50 per
field of view) were counted for 15 fields of view, and
the numbers of bacteria were determined by using the
following equation:
DF  ACC  6; 732:42  50  DFsample
where the DF (dilution factor) was calculated by taking
into account the concentration of the original sample
(375 to 300 μL = 0.8×). ACC (average cell count) was
determined by counting 15 fields of view and assumes
that a normal distribution was observed for the counts.
The figure 6732.42 refers to the area of the well divided
by the area of the field of view. DFsample refers to the
dilution of sample used with a particular probe (e.g. 5×
for t0 Lab158 counts). The detection limit of this
method was 89,766 bacteria/mL of sample (= log10 4.95).
Screening of bacteria for ability to reduce TMAO
Part of an in-house collection (University of Reading) of
bacteria isolated from human caecal/small intestinal and
faecal samples (Table 1) was screened on minimal agar
[g/L: glucose (Fisher Scientific), 4; bacteriological pep-
tone (Oxoid), 20; NaCl (Fisher Scientific), 5; neutral red
(Sigma-Aldrich), 0.03; agar technical no. 3 (Oxoid), 15;
pH 7] with and without 1% (w/v) TMAO dihydrate
(Sigma-Aldrich). The composition of the agar was based
on [27], who used the medium with crystal violet and
bile salts to screen members of the Enterobacteriaceae
for TMAO reductase activity. Colonies of isolates able to
ferment glucose were red, whereas those able to reduce
TMAO were white. Growth curves (OD600 measured
hourly for 10–12 h, then at 24 h) were determined for
selected isolates grown anaerobically at 37 °C in anaer-
obic minimal broth [g/L: glucose, 4; bacteriological pep-
tone, 20; NaCl, 5; L-cysteine HCl (Sigma-Aldrich), 0.5;
resazurin solution (0.25 mg/mL; Sigma-Aldrich), 4 mL;
pH 7] with and without 1% (w/v) TMAO dihydrate.
Glucose was substituted by raffinose (Sigma-Aldrich)
[33] in the minimal broth when working with bifidobac-
teria because of the poor growth of these bacteria on the
glucose-based medium. pH and metabolite profiles of
culture medium were examined at the end of the growth
experiment (i.e. at t24).
Statistical analyses
Differences between metabolites produced by faecal and
caecal/small intestinal isolates of Escherichia coli and
lactic acid bacteria in the presence and absence of
TMAO were analysed using Student’s t test. FISH data
from the in vitro fermentation systems were analysed
using the Kolmogorov–Smirnov test with statistical
significance, after correction for multiple testing, taken
at P < 0.05. Because of the presence of ties in the metab-
olite data from in vitro fermentation systems, the boot-
strapped Kolmogorov–Smirnov test (10,000 replications)
was used with these data. Data from in vitro fermenta-
tion systems (FISH and NMR) were correlated using
Spearman’s rank correlation (corrected for ties) with
results corrected for multiple testing using the method
of Benjamini and Hochberg [34].
Results
In vivo confirmation of metabolic retroconversion
First, to confirm in vivo metabolic retroconversion (i.e.
microbial conversion of TMAO to TMA, followed by
host conversion of TMA to TMAO), we administered
isotopically labelled d9-TMAO or saline to mice that had
or had not been treated with a broad-spectrum anti-
biotic cocktail for 14 days to suppress the gut microbiota
[12]. Reduction of d9-TMAO to d9-TMA was quantified
in urine by UPLC–MS/MS up to 6 h after d9-TMAO
gavage, together with unlabelled TMA and TMAO
potentially produced from dietary sources (Fig. 1).
In the absence of antibiotics, d9-TMAO was converted
to d9-TMA within 2 h of gavage. This conversion was
dramatically reduced, leading to a significantly lower
concentration of d9-TMA and a higher concentration of
d9-TMAO, when the gut microbiota was suppressed by
antibiotics (Fig. 1a–d). We noted that in the absence of
antibiotics, all animals excreted approximately three
times higher levels of urinary unlabelled TMA than
TMAO (Fig. 1e–h), corresponding to constitutively low
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Table 1 Details for human-derived gut bacteria screened for their ability to reduce or utilize TMAO
Isolate* Identified as Source Reference Facultative anaerobe?
D2(9) [Clostridium] innocuum Human faeces M.L. Jiménez-Pranteda, unpublished No
L16-FAA1 [Clostridium] ramosum Human caecum L. Hoyles, unpublished No
L12-BSM1 Actinomyces odontolyticus Human caecum L. Hoyles, unpublished No
L6-BSM10 Actinomyces viscosus Human caecum L. Hoyles, unpublished No
L6-FAA7 Bacteroides fragilis Human caecum L. Hoyles, unpublished No
D1(4) Bacteroides vulgatus Human faeces M.L. Jiménez-Pranteda, unpublished No
L9-FAA7 Bacteroides vulgatus Human caecum L. Hoyles, unpublished No
DSM 20083T Bifidobacterium adolescentis Human intestine DSMZ† No
LCR26 Bifidobacterium animalis subsp. lactis Infant faeces [51] No
LCR11 Bifidobacterium bidifum Infant faeces [51] No
L25-MRS2 Bifidobacterium bifidum Human caecum L. Hoyles, unpublished No
LCR5 Bifidobacterium breve Infant faeces [51] No
LCR8 Bifidobacterium breve Infant faeces [51] No
LCR1 Bifidobacterium dentium Infant faeces [51] No
DSM 20093T Bifidobacterium gallicum Human intestine DSMZ No
LCR6 Bifidobacterium longum Infant faeces [51] No
DSM 20088T Bifidobacterium longum subsp. infantis Infant intestine DSMZ No
LCR2 Bifidobacterium longum subsp. infantis Infant faeces [51] No
DSM 20219T Bifidobacterium longum subsp. longum Human intestine DSMZ No
LCR3 Bifidobacterium pseudocatenulatum Infant faeces [51] No
L19-MRS1 Bifidobacterium longum subsp. longum Human caecum L. Hoyles, unpublished No
L25-MRS8 Bifidobacterium longum subsp. longum Human caecum L. Hoyles, unpublished No
L26-MRS4 Bifidobacterium animalis subsp. lactis Human caecum L. Hoyles, unpublished No
L26-FAA1 Citrobacter gillenii Human caecum L. Hoyles, unpublished Yes
L8-FAA3 Citrobacter koseri Human caecum L. Hoyles, unpublished Yes
L16-FAA6 Clostridium paraputrificum Human caecum L. Hoyles, unpublished No
L20-BSM1 Clostridium perfringens Human caecum L. Hoyles, unpublished No
D1(9) Clostridium sporogenes Human faeces M.L. Jiménez-Pranteda, unpublished No
D2(14) Enterococcus faecalis Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D3(1) Enterococcus faecalis Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D5(2) Enterococcus faecalis Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D6(1) Enterococcus faecium Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D6(5) Enterococcus gallinarum Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D1(2) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D2(1) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D2(2) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D2(8) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D3(8) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D4(15) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D5(1) Escherichia coli Human faeces M.L. Jiménez-Pranteda, unpublished Yes
L1-FAA5 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L13-FAA2 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L16-FAA5 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L19-FAA2 Escherichia coli Human caecum L. Hoyles, unpublished Yes
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FMO3 activity in mice [35]. Levels of unlabelled
TMAO/TMA were not significantly different from one
another in the control and d9-TMAO-fed animals, while
antibiotic treatment significantly reduced the amount of
both TMAO and TMA (Fig. 1e, f ). Bioavailability of
unlabelled TMAO/TMA, as assessed by area under the
curve (AUC), was significantly reduced by antibiotic
treatment in both saline and d9-TMAO-gavaged animals,
with almost no TMA detected in either experimental
group (Fig. 1g, h).
Effect of TMAO on human gut bacteria within a mixed
system
After in vivo validation of the role of the gut microbiota
in metabolic retroconversion, we analysed the effect of
TMAO on the faecal microbiota in an anaerobic batch-
culture fermentation system. Fermenter vessels filled
with the glucose-containing medium supplemented or
not with 1% (w/v) TMAO were inoculated with faecal
slurries from three healthy donors and monitored for
9 h. With the exception of enhanced growth of the
Enterobacteriaceae (probe Ent), the presence of TMAO
in the medium had no statistically significant effect on
the growth of bacteria within the fermentation systems
at 9 h (Fig. 2a, Additional file 1: Figure S1).
Huge variability, as measured by 1H-NMR, was
observed in the amount of TMA and DMA produced by
gut bacteria in the TMAO-containing fermentation
systems, with the concentrations of both metabolites
increasing steadily from 0 to 9 h and differing signifi-
cantly (P < 0.05) from the control systems (Fig. 2b). The
amount of TMAO in the systems was seen to decrease
at 8 h.
Correlation of metabolite and FISH data demonstrated
Clostridium clusters I and II (Chis150), Enterobacteriaceae
(Ent), bifidobacteria (Bif164) and coriobacteriia (Ato291)
were associated with TMA, acetate, ethanol, and lactate
(Fig. 2c). The Betaproteobacteria (Bet42a) were anti-
correlated with TMA, acetate, ethanol, and lactate, which
is unsurprising given this was the only group of bacteria
whose representation decreased in the fermentation sys-
tems over the course of the experiment (Additional file 1:
Figure S1, Fig. 2c). The Enterobacteriaceae and clostridia
were positively correlated with DMA production. The
lactic acid bacteria (Lab158) were not significantly corre-
lated with any of the metabolites in the mixed culture.
Table 1 Details for human-derived gut bacteria screened for their ability to reduce or utilize TMAO (Continued)
Isolate* Identified as Source Reference Facultative anaerobe?
L20-FAA3 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L24-FAA5 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L5-FAA2 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L6-FAA1 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L9-MRS1 Escherichia coli Human caecum L. Hoyles, unpublished Yes
L9-FAA5 Fusobacterium ulcerans Human caecum L. Hoyles, unpublished Yes
L15-FAA9 Hafnia paralvei Human caecum L. Hoyles, unpublished No
L4-FAA5 Klebsiella pneumoniae subsp. pneumoniae Human caecum [52] Yes
L26-MRS5 Lactobacillus fermentum Human caecum L. Hoyles, unpublished No
L26-FAA6 Lactobacillus rhamnosus Human caecum L. Hoyles, unpublished No
L13-FAA10 Parabacteroides johnsonii Human caecum L. Hoyles, unpublished No
D4(1) Paraclostridium bifermentans Human faeces M.L. Jiménez-Pranteda, unpublished No
L1-FAA6 Pseudomonas aeruginosa Human caecum L. Hoyles, unpublished Yes
D2(4) Staphyloccoccus hominis Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D1(5) Streptococcus anginosus Human faeces M.L. Jiménez-Pranteda, unpublished Yes
D5(12) Streptococcus anginosus Human faeces M.L. Jiménez-Pranteda, unpublished Yes
L25-MRS1 Streptococcus gallolyticus Human caecum L. Hoyles, unpublished Yes
L4-MRS5 Streptococcus oralis Human caecum L. Hoyles, unpublished Yes
L4-MRS1 Streptococcus sanguinis Human caecum L. Hoyles, unpublished Yes
D4(3) Streptococcus sp. Human faeces M.L. Jiménez-Pranteda, unpublished Yes
L26-MRS7 Streptococcus vestibularis Human caecum L. Hoyles, unpublished Yes
LCR4 Unknown Bifidobacterium Infant faeces [51] No
*Ln- prefix, different numbers indicate isolates recovered from different individuals
†DSMZ, Leibniz Institute DSMZ – German Collection of Microorganisms and Cell Cultures
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Fig. 1 (See legend on next page.)
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Fig. 1 In vivo confirmation of metabolic retroconversion of TMAO. Reduction of d9-TMAO to d9-TMA was quantified by UPLC–MS/MS up to 6 h after
d9-TMAO gavage and antibiotic treatment, together with unlabelled TMA and TMAO levels. Plasma quantification of post-gavage a d9-TMA and b
d9-TMAO. *Significantly (P < 0.05; t test and corrected for multiple comparison using the Holm–Sidak method) different from the respective groups not
treated with antibiotics. c d9-TMA bioavailability (AUC). d d9-TMAO bioavailability (AUC). Plasma quantification of post-gavage unlabelled/endogenous
e TMA and f TMAO. *Significant between d9 and d9 antibiotic treatment;
$significant between TMAO and TMAO antibiotic treatment. g Unlabelled/
endogenous TMA bioavailability (AUC). h Unlabelled/endogenous TMAO bioavailability (AUC). Data (n = 6 per group) are shown as mean ± SEM (a, b,
e, f). Differences between the bioavailabilities (c, d, g, h) were assessed using one-way analysis of variance (ANOVA), followed by Holm–Sidak post hoc
tests. Data with different superscript letters are significantly different (P < 0.05)
Fig. 2 Effect of TMAO on mixed faecal microbial population in vitro. a Enumeration of selected bacteria in fermentation vessels by FISH analysis. Red
lines, TMAO-containing systems; blue lines, negative controls. Data are shown as mean + SD (n = 3). Eub338, total bacteria; Ent, Enterobacteriaceae;
Bif164, Bifidobacterium spp.; Lab158, lactic acid bacteria. *Statistically significantly different (adjusted P < 0.05) from the control at the same time point.
Full data are shown in Additional file 1: Figure S1. b 1H-NMR data for batch culture samples. Data are shown as mean ± SD (n = 3). Red lines, TMAO-
containing systems; blue lines, negative controls. *Statistically significantly different (P < 0.05) from the negative control at the same time point. c
Bidirectional clustering of correlation matrix of FISH data and data for the six metabolites found in the highest amounts in the NMR spectra from the
batch-culture samples. +Adjusted P value (Benjamini–Hochberg) statistically significant (P < 0.05). FISH and metabolite data and a table of correlations
and adjusted P values (Benjamini–Hochberg) for the batch-culture samples are available in Additional file 1: Table S3–S5
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Growth of pure cultures of gut bacteria in the presence
of TMAO
Using an in-house collection of bacteria, we initially
screened isolates on a modified version of the agar of
Takahi and Ishimoto [27] as a rapid means of screening
bacteria for TMAO reductase activity, and thereby their
ability to reduce TMAO to TMA. While members of the
Enterobacteriaceae produced expected results (i.e. white
colonies when grown in the presence of TMAO and
glucose, rather than red colonies on the glucose only
control), we observed a number of unexpected outcomes
depending on the species under study. For example,
colonies of lactic acid bacteria were larger (almost twice
their usual size) on TMAO-containing agar than on the
glucose control but remained red in colour, suggesting
they had not reduced TMAO to TMA at detectable
levels but TMAO was influencing their growth. The
clostridia examined produced mixed results on the con-
trol and TMAO-containing media (i.e. white colonies on
both plates or on the control plate only, larger colonies
on the TMAO-containing medium but without a colour
change of the medium).
To determine whether these isolates were converting
TMAO to TMA but a low level, we examined the
growth of all isolates in liquid culture and metabolites
in the spent medium using NMR. The growth of the
Enterobacteriaceae was most greatly affected by the
presence of TMAO in the medium, with a faster,
longer-lasting exponential phase than for the same
isolates grown in the control medium (Fig. 3a). pH of
the spent medium (after 24 h) when Enterobacteria-
ceae were grown in the presence of TMAO increased
from a mean of 4.7 ± 0.3 (for the control) to 7.6 ± 0.3
(n = 20) (the change in pH is what causes the colonies
to appear white on TMAO-containing agar). The
growth of lactic acid bacteria, including Enterococcus
and Streptococcus (Fig. 3a) spp., was enhanced in the
presence of TMAO, but not to the same extent as seen
for the Enterobacteriaceae. There was no significant
difference (P = 0.27, t test) in the pH of the spent
medium for these bacteria after 24 h (mean 4.67 ± 0.9
compared with 4.33 ± 0.27 for the control). The
growth of members of Clostridium cluster I (e.g. Clos-
tridium perfringens, Fig. 3a) was not enhanced in the
presence of TMAO, though some of these bacteria
changed the colour of both the control and TMAO-
containing plates yellow during their growth. The pH
of the spent liquid medium confirmed this observation
to be due to the alkalinity of the media in the control
and TMAO-containing media after 24-h incubation: e.
g. Clostridium sporogenes D1(9) (pH 6.25 compared
with 6.76 in the control medium), Clostridium para-
putrificum L16-FAA6 (pH 6.45 vs 5.38), and Clostrid-
ium perfringens L20-BSM1 (pH 5.56 vs 4.64).
1H-NMR analysis of spent medium from the TMAO-
containing and control samples demonstrated that, as
expected, the Enterobacteriaceae produced the greatest
amount of TMA from TMAO (mean 38.79 ± 11.08 mM
compared with 0.03 ± 0.01 mM, n = 20) (Fig. 3b;
Additional file 1: Table S2). Members of the families
Peptostreptococcaceae (3.72 mM, n = 1), Clostridiaceae
(cluster I) (2.62 ± 1.83 mM, n = 3), Porphyromonadaceae
(1.42 mM, n = 1), Bacteroidaceae (1.40 ± 0.31 mM, n = 3),
Enterococcaceae (1.19 ± 0.05 mM, n = 5), Erysipelotricha-
ceae (0.94 mM, n = 1; [Clostridium] ramosum), Staphylo-
coccaceae (0.34 mM, n = 1), Streptococcaceae (0.30 ±
0.16 mM, n = 5), Lactobacillaceae (0.17 ± 0.07 mM,
n = 2), Pseudomonadaceae (0.12 mM, n = 1), and Bifido-
bacteriaceae (0.13 ± 0.1 mM, n = 17) produced low levels of
TMA from TMAO (Fig. 3b; Additional file 1: Table S2).
There was great variability in the ability of the bifidobacteria
to produce TMA from TMAO, with several isolates and
[Clostridium] innocuum, Actinomyces odontolyticus, Fuso-
bacterium ulcerans, and Actinomyces viscosus not producing
TMA from TMAO (Fig. 3b; Additional file 1: Table S2).
Differences in the metabolic capabilities of faecal and
caecal Escherichia coli isolates
Comparison of the amounts of TMA, and co-metabolites,
produced by the faecal (n = 7) and caecal (n = 9) isolates of
Escherichia coli demonstrated significantly higher amounts
of TMA were produced by the caecal isolates compared
with the faecal isolates in the TMAO-containing medium
(Fig. 3c). Escherichia coli of caecal origin produced more
TMA than faecal isolates of the same bacterium or other
enterobacteria (Hafnia, Citrobacter, and Klebsiella spp.)
(Additional file 1: Table S2). The faecal isolates produced
more acetate and lactate than the caecal isolates when
grown in the control medium. Taken together, these results
demonstrate the different metabolic capabilities of isolates
of Escherichia coli recovered from different regions of the
human gut.
Lactic acid bacteria produce more lactate in the presence
of TMAO
Differences were also seen in the amount of lactic acid
produced by lactic acid bacteria in the presence and
absence of TMAO (Fig. 3b, d). In raffinose-containing
medium, bifidobacteria produced increased amounts of
lactate when grown in the presence of TMAO (the bifi-
dobacteria grew poorly, if at all, in glucose-containing
media). Unlike the bifidobacteria, the Streptococcaceae
and Enterococcaceae grew well in the glucose-containing
medium and produced over 25 mM lactic acid in the
TMAO-containing samples compared with < 5 mM in
the control samples (Fig. 3d). To the best of our know-
ledge, this is the first time TMAO has been shown to
influence the metabolism of gut bacteria—specifically lactic
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acid bacteria—without producing appreciable amounts of
TMA.
Discussion
TMAO is a circulating metabolite produced as a direct
result of microbial degradation of dietary methylamines
in the intestinal tract and can be readily detected along
with its precursor TMA in human urine, blood, and
skeletal muscle [8, 12, 18, 22]. It worsens atherosclerosis
in some mouse models of CVD and is positively corre-
lated with CVD severity in humans. Beneficial effects
associated with TMAO include potential protection
from hyperammonemia and glutamate neurotoxicity, al-
leviation of endoplasmic reticulum stress, and improved
glucose homeostasis by stimulating insulin secretion by
pancreatic cells [10, 15, 16].
Over many decades, it has been established that choline,
PC, and carnitine are dietary methylamines that contrib-
ute directly to microbiome-associated circulating levels of
TMAO found in humans and other animals—e.g. [2, 12,
18, 19, 21, 22]. However, TMAO itself is a water-soluble
osmolyte found in high abundance in fish. Based on their
Fig. 3 Influence of TMAO on growth and metabolism of pure cultures of gut bacteria. a Representative growth curves for isolates grown in the presence
and absence of TMAO. Red lines, TMAO-supplemented cultures; blue lines, negative controls. Data are shown as mean ± SD (n= 3). b Biplot showing
production of various metabolites when isolates were grown in the presence of TMAO. Summary of data from Additional file 1: Table S2. The larger a circle,
the more of the metabolite produced by an isolate. c Differences in metabolites produced when caecal and faecal isolates of Escherichia coli were grown
in the presence (+) and absence (−) of 1% TMAO. Adjusted (Benjamini–Hochberg) P values indicate the caecal isolates were significantly different from the
faecal isolates for a particular metabolite. d Lactate production by lactic acid bacteria was increased in the presence of TMAO. Enterobacteriaceae, n= 20;
Bifidobacteriaceae, n= 17; Streptococcaceae, n= 7; Enterococcaceae, n= 5. Members of the Enterococcaceae and Streptococcaceae are homofermenters
(produce only lactic acid from glucose fermentation), whereas the Bifidobacteriaceae are heterofermenters (produce ethanol, CO2, and lactic
acid from glucose fermentation), though it should be noted the bifidobacteria included in this study were grown on raffinose-containing media. Red,
TMAO-containing medium; blue, negative control. *Statistically significantly different from its negative control (adjusted P value < 0.05)
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observations that individuals with trimethylaminuria could
reduce an oral dose of TMAO to TMA but could not
detoxify it to TMAO, al-Waiz et al. [25] suggested the gut
microbiota could use TMAO as a substrate, and in those
individuals without trimethylaminuria, the TMA was
re-oxidized in the liver before being excreted in the urine.
This led these authors to propose the process of metabolic
retroversion. Reference to the literature associated with
fish spoilage and recent mining of metagenomic data have
predicted members of the Enterobacteriaceae (particularly
Escherichia coli and Klebsiella pneumoniae) have the
potential to convert TMAO to TMA in the intestinal
tract, but this has not been tested in vitro or in vivo to
date [4, 8, 26–28]. Consequently, we instigated this study
to demonstrate metabolic retroconversion of TMAO and
to determine the effect of TMAO on the growth and
metabolism of human-derived intestinal bacteria in pure
and mixed cultures.
Through in vivo administration of deuterated TMAO
to mice via oral gavage in mice, we unambiguously dem-
onstrated that TMAO is converted to TMA, with this
TMA detectable in plasma within 2 h of administration.
This conversion was highly dependent on the gut micro-
biota, as conversion of TMAO to TMA was dramatically
reduced when the microbiota was suppressed by treat-
ment of animals with broad-spectrum antibiotics. Even
in the presence of antibiotics, there was low-level con-
version of TMAO to TMA, suggesting a subpopulation
of the microbiota was resistant to the antibiotics used in
our experiment. However, administration of a broad-
spectrum antibiotic cocktail for 14 days has been dem-
onstrated to be an effective means of suppressing the
gut microbiota in studies associated with gut microbial
use of dietary methylamines [12].
Our in vivo experiment clearly demonstrates the gut
microbiota converts TMAO to TMA and that this TMA
is re-oxidized to TMAO, in line with the process of
metabolic retroversion [25]. Gut-associated microbial
conversion of the majority of TMAO to TMA is at odds
with recent findings [8], in which it was suggested
TMAO is taken up intact and not metabolized by the
gut microbiota of humans. The ratio of TMAO-to-TMA
is around 10:1 in humans and 1:10 in mice, meaning
TMAO was N-oxidized before Taesuwan et al. [8] were
able to observe it in circulating blood of their human
subjects. In a human system with high FMO3 activity,
17O-labelled TMAO would need to be used in any study
evaluating O turnover to allow calculation of the true
rate of retroconversion.
Based on work done in mice [10, 36], metabolic retro-
conversion of TMAO may be protective and may even
go some way to explaining why TMA and TMAO are
detected at low levels in urine in the absence of dietary
methylamines [17]. Chronic exposure of high-fat-fed
mice to TMAO reduced diet-associated endoplasmic
stress and adipogenesis and improved glucose tolerance
[10]. Exposure of high-fat-fed mice to TMA reduced low-
grade inflammation and insulin resistance via inhibition of
interleukin-1 receptor-associated kinase 4 (IRAK-4) [36].
Concentrations of the microbial signalling metabolite
TMA used by Chilloux et al. [36] were comparable to
those found in normal human plasma. Continual exposure
of the human system to TMA/TMAO may bring similar
benefits to host metabolic and inflammatory responses;
these remain to be studied.
Having conducted our in vivo experiment in mice, we
examined the ability of a range of human-derived gut
bacteria to convert TMAO to TMA. In the mixed
microbiota system and in pure cultures, the growth of
the Enterobacteriaceae—the main TMA producers—was
quickly affected by the presence of TMAO. This is likely
to happen in the human gut also. Consequently, we
believe dietary TMAO undergoes metabolic retroconver-
sion in mammals, with the TMA produced as a result of
bacterial activity in the gut available to the host for con-
version back to TMAO by FMOs in hepatocytes. It
should be noted that [8] did not suppress or monitor the
intestinal/faecal microbiota when they administered iso-
topically labelled TMAO to humans, nor did they meas-
ure d9-TMA and d9-TMAO in the portal vein, bypassing
subsequent hepatic N-oxidation of d9-TMA, so it is not
possible to interpret their results in the context of the
presence/absence of microbial activity.
Of note is the finding that caecal isolates of enterobac-
teria produce more TMA from TMAO than faecal isolates
of the same bacterium. The speed with which TMAO was
reduced to TMA by the Enterobacteriaceae in the present
study suggests bacterial conversion of TMAO to TMA
takes place in the small intestine/proximal colon of humans
and small intestine/caecum of mice. It is, therefore, unsur-
prising that caecal bacteria—representing the microbiota
present at the intersection of the small and large intestine—
are metabolically more active than their faecal counterparts
with respect to TMAO metabolism. This finding is relevant
to functional studies of the gut microbiota where gene
annotations are based largely on faecal isolates, whose func-
tionalities may be greatly different from those of bacteria in
other regions of the human intestinal tract [37, 38]. It has
already been demonstrated that the microbiota of the small
intestine is enriched for functions associated with rapid
uptake and fermentation of simple carbohydrates compared
with the faecal microbiota and that streptococci isolated
from this niche are functionally very different from the
same bacteria isolated from different habitats [37, 38]. It is,
therefore, important that we characterize the functions and
genomes of bacteria isolated from all regions of the intes-
tinal tract, not just those of faecal bacteria, to gain a true
picture of how microbial activity influences host health.
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Enterobacteriaceae made the greatest contribution to the
conversion of TMAO to TMA, both in pure culture and in
a mixed microbiota. These Gram-negative bacteria are a
source of the virulence factor lipopolysaccharide (LPS),
which is associated with low-grade inflammation in high-
fat-fed mice and elevated plasma levels that define meta-
bolic endotoxaemia [39, 40]. High-fat feeding has been
shown to increase the representation of Enterobacteriaceae
in the caecal microbiota of obesity-prone Sprague Dawley
rats [41], though this mode of feeding is known to modu-
late the microbiota of mice independent of obesity [42].
Non-LPS-associated virulence of Enterobacteriaceae,Vibrio
cholerae, and Helicobacter pylori is increased when these
bacteria are grown anaerobically or microaerophilically in
the presence of as little as 5–10 mM TMAO [43–46], and
may be an additional means by which the gut microbiota
contributes to CVD and other diseases in which increased
representation of Gammaproteobacteria is observed. This
warrants attention in future animal studies.
Lactic acid bacteria clearly grow better in the presence
of TMAO. The relatively high concentration (1%) of
TMAO used in this study may have contributed to this
improved growth, as TMAO is an osmolyte that stabilizes
proteins. Future work will involve growing lactic acid
bacteria in a range of TMAO concentrations to determine
how this compound affects their growth and gene expres-
sion, and comparing faecal and caecal isolates. Similar to
the Enterobacteriaceae, a large number of these bacteria
are facultative anaerobes able to grow over a range of
conditions, and whose representation is increased in
obese, and cirrhotic patients [47, 48]. Streptococcus and
Enterococcus spp. are commensal lactic acid bacteria of
the gut microbiota known to modulate immune function,
but little is known about their metabolic activities in
mixed microbial populations [49]. Understanding how
commensal lactic acid bacteria influence the host in
dysbiosis in mixed microbial communities may allow the
development of approaches to modulate their activity and
influence host health.
With respect to the lactic acid bacteria, it is important
to note that our mixed culture work did not highlight
these as being relevant to TMAO metabolism. This is
unsurprising given these bacteria do not produce large
quantities of TMA from TMAO. However, we have
shown their metabolism is affected by the presence of
TMAO in growth medium, and the increased lactate
they produce in its presence may contribute to cross-
feeding associated with short-chain fatty acid production
[50]. It is difficult to determine the relevance of correla-
tions from mixed microbial ecosystems in the absence of
isotope labelling or pure culture work, i.e. correlation
does not equate with causation. As an example, three
(Clostridium clusters I and II, bifidobacteria, coriobac-
teriia) of the four groups of bacteria correlated with
TMA production in our fermentation study did not pro-
duce notable quantities of TMA from TMAO based on
our pure culture work. Therefore, correlating microbiota
and metabolite data derived from complex systems will
not give a true picture of which members of microbiota
contribute to specific metabolic processes, and work
with pure cultures is required to supplement functional
studies to increase our understanding of poorly under-
stood microbially driven metabolic processes within the
human gut.
Conclusions
We have demonstrated metabolic retroconversion—an-
other example of host–microbial co-metabolism—occurs
in the mammalian system with respect to TMAO,
whereby TMAO is reduced by the gut microbiota to
TMA and regenerated by host hepatic enzymes. We
have also demonstrated that growth and metabolism of
members of the gut microbiota are affected by TMAO
in a source- and taxon-dependent manner, with the fam-
ily Enterobacteriaceae making the greatest contribution
to production of TMA in the gut.
Additional file
Additional file 1: Figure S1. Effect of TMAO on mixed faecal microbial
population in vitro. Enumeration of bacteria in fermentation vessels by FISH
analysis. Red lines, TMAO-containing systems; blue lines, negative controls.
Data are shown as mean + SD (n = 3). Eub338, total bacteria; Bac303,
Bacteroidales; Ato291, “Atopobium cluster”; Bif164, Bifidobacterium spp.;
Ent, Enterobacteriaceae; Bet42a, Betaproteobacteria; Prop853, Veillonellaceae;
Lab158, lactic acid bacteria (Lactobacillales); Fpra655, Faecalibacterium prausnitzii
and Subdoligranulum spp.; Erec482, Lachnospiraceae; Clit135, Clostridium cluster
XI; Rbro730/Rfla729, Ruminococcaceae; Chis150, Clostridium clusters I and II.
Detection limit of the method was 4.95 log10 (number of bacteria/mL sample).
*Statistically significantly different (adjusted P< 0.05) from the control at the
same time point. Table S1. Oligonucleotide probes used in this study.
Table S2. NMR-based analysis of metabolites in growth medium of
pure cultures after 24-h incubation (anaerobic) in the presence and
absence of TMAO. Table S3. FISH data for the batch culture samples,
with data presented as log10 (number of bacteria/mL sample). Table S4.
NMR data for the batch culture samples, with concentrations of metabolites
given in mM. Table S5. Spearman correlation (corrected for ties) and
adjusted P values (Benjamini–Hochberg) for FISH and metabolite data for
batch culture samples. (DOCX 227 kb)
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